Belgian consensus recommendations for flow cytometric immunophenotyping

Acta Clinica Belgica

Volumn 54, Issue 2, 1999, Pages 88-98

  Van Bockstaele, Dirk R ^a   Deneys, Véronique ^b   Philippé, Jan ^c   Bernier, Michel ^d   Kestens, Luc ^e   Châtelain, Bernard ^f   De Waele, Marc ^g   Demanet, Christian ^g  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^g UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Flow cytometry; Haematology; Immunophenotyping; Leukaemia; Lymphoma

Indexed keywords

ANTIGEN; CD45 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LEUKEMIA; ALGORITHM; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; INFECTION; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PLASMA CELL DYSCRASIA; PRACTICE GUIDELINE; STEM CELL;

EID: 0032977442     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Coon JS, Landay AL, Weinstein RS. Biology of disease. Advances in flow cytometry for diagnostic pathology. Laboratory Investigation 1987; 57: 453-479.
2. Ryan DH, Fallon MA, Horan PK. Flow cytometry in the clinical laboratory. Clinica Chimica Acta 1988; 171: 125-174.
3. Freedman AS. Cell surface antigens in leukemias and lymphomas. Cancer Investigation. 1996; 14: 252-276.
4. Garand R and Robillard N. Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. Hematol Cell Ther. 1996; 38: 471-486.
5. Jennings CD and KA Foon. Recent advances in flow cytometry: Application to the diagnosis of hematological malignancy. Blood. 1997; 90 : 2863-2892.
6. Jennings CD and Foon KA. Flow cytometry: Recent advances in diagnosis and monitoring of leukemia. Cancer Investigation. 1997; 15: 384-399.
7. Nicholson JK. Use of flow cytometry in the evaluation and diagnosis of primary and secondary immunodeficiency diseases. Arch Pathol Lab Med 1989; 113: 598-605.
8. Michelson AD. Flow Cytometry: A clinical test of platelet function. Blood 1996; 87: 4925-4936.
9. Hulstaert F, Albrescht J, Hannet I, Lancaster P, Buchner L, Kunz J, Falkenrodt A, Tongio M, De Keyser F, Veys E. et al. An optimized method for routine HLA-B27 screening using flow cytometry. Cytometry 1994; 18: 21-29.
10. Lingenfelter B, Fuller T, Hartung L, Hunter J, Wittwer C. HLA-B27 screening by flow cytometry. Cytometry 1995; 22: 146-149.
11. Ward A, Nikaen A. Comparison of monoclonal antibodies for flow cytometric analysis of HLA-B27 antigen. Cytometry 1995; 22: 65-69.
12. Hoffmann J, Janssen W. HLA-B27 phenotyping with flow cytometry: further improvement by multiple monoclonal antibodies. Clin Chem 1997; 43: 1975-1981.
13. Rothe G and Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996; 10: 877-895.
14. Stelzer G, Marti G, Hurley A, McCoy P, Lovett E, Schwartz A. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Standardization and validation of laboratory procedures. Cytometry 1997; 30: 214-230.
15. Stewart C, Behm F, Carey J, Cornbleet J, Duque R, Hudnall D, Hurtubise P, Loken M, Tubbs R, Wormsley S. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Selection of antibody combinations. Cytometry 1997; 30: 231-235.
16. Borowitz M, Bray R, Gascoyne R, Melnick S, Parker J, Picker L, Stetler-Stevenson M. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation. Cytometry 1997; 30: 236-244.
17. Braylan R, Atwater S, Diamond L, Hassett J, Johnson M, Kidd P, Leith C, Nguyen D. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data reporting. Cytometry 1997; 30: 245-248.
18. Davis B, Foucar K, Szczarkowski W, Ball E, Witzig T, Foon K, Wells D, Kotylo P, Johnson R, Hanson C, Bessman D. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Medical indications. Cytometry 1997; 30: 249-263.
19. Johnson E. for the Nordic Myeloma Study Group Laboratories: Report from a Nordic workshop on CD34+ cell analysis: Technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. J Hematother 1995; 4: 21-28.
20. Chang A, Ma D. The influence of flow cytometric gating strategy on the standardization of CD34+ cell quantitation: an Australian multicenter study. Australasian BMT Scientists Study Group. J Hematother 1996; 5: 605-616.
21. Sutherland D, Anderson L, Keeney M, Nayr R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213-226.
22. Johnson H, Knudsen L, for the Nordic Stem Cell Laboratory Group: Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: Report from the second Nordic workshop. J Hematother 1996; 5: 237-245.
23. Gratama J, Kraan J, Levering W, Van Bockstaele D, Rijkers G, Van der School E. Analysis of variation in results of CD34+ hematopoietic progenitor cell enumeration in a multicenter study. Cytometry 1997; 30: 109-117.
24. Gratama JW, Orfao A, Barnett D, Brando B, Huber A, Janossy G, Johnsen HE, Keeney M, Marti GE, Preijers F, Rothe G, Serke S, Sutherland DR, Van der School CE, Schmitz G, Papa S. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. Cytometry 1998; 34: 128-142.
25. Centers for Disease Control and Prevention. 1997 Revised guidelines for the performance of CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR 1997; 46 (No.RR-2): 1-29.
26. Nicholson J, Kidd P, Mandy F, Livnat D, Kagan J. Three-color supplement to NIAID DAIDS Guideline for flow cytometric immunophenotyping. Cytometry 1996; 26: 227-230.
27. Hedley DW, Shankey TV, Wheeless LL. DNA cytometry consensus conference. Cytometry 1993; 14: 471.
28. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, Mayall BH, Wheeless L, Cox C. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 1993; 14: 472-477.
29. Wheeless LL, Badalament RA, de Vere White RW. Fradet Y, Tribukait B. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. Cytometry 1993; 14: 478-481.
30. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry 1993; 14: 482-485.
31. Bauer KD, Bagwell CB, Giaretti W, Melamed M, Zarbo RJ, Witzig TE, Rabinovitch PS. Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry 1993; 14: 486-491.
32. Duque RE, Andreeff M, Braylan RC, Diamond LW, Peiper SC. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993; 14: 492-496.
33. Shankey TV, Kallioniemi OP, Koslowski JM, Lieber ML, Mayall BH, Miller G, Smith GJ. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 1993; 14: 497-500.
34. Hassett J, Parker J. Laboratory practices in reporting flow cytometry phenotyping results for leukemia/lymphoma specimens: results of a survey. Cytometry 1995; 22: 264-81.
35. Paxton H, Bendele T. Effect of time, temperature and anticoagulant on flow cytometry and hematological values. Ann NY Acad Sci 1993; 677: 440-443.
36. Stelzer G, Marti G, Hurley A, McCoy P, Lovett E, Schwartz A. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Standardization and validation of laboratory procedures. Cytometry 1997; 30: 214-230.
37. Clark P, Normansell DE, Innes DJ, Hess CE. Lymphocyte subsets in normal bone marrow. Blood 1986; 67: 1600-1606.
38. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the international lymphoma study group classification of Non-Hodgkin's lymphoma. Blood 1997; 89: 3909-3918.
39. Matutes E and Catovsky D. The value of scoring systems for the diagnosis of biphenotypic leukaemia and mature B-cell disorders. Leuk Lymph. 1994; 13: 11-14.
40. Moreau E, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK, Catovsky D. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol. 1997; 108: 378-382.
41. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C, The French-American-British (FAB) cooperative group. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol. 1989; 42: 567-584.
42. N.L. Harris, E.S. Jaffe, H. Stein, P.M. Banks, J.K.C. Chan, M. Cleary, G. Delsol, C. De Wolf-Peeters, B. Falini, K.C. Gatter, T.M. Grogan, P.G. Isaacson D.M. Kowles, D.Y. Mason, H.-K. Muller-Hermelink, S.A. Pileri, M.A. Piris, E. Ralfikiaer, R.A. Warnke. A revised European-American classification of lymphoid neoplasms: a proposal from the international study group. Blood. 1994; 84: 1361-1392.
43. Deneys V, Leveugle P, Hougardy N, Mazzon AM, Michaux L, De Bruyere M. What to do with a chronic B lymphoproliferative disorder with a matutes's score less than three? In: Abstracts book of the 13th general meeting of the Belgian hematological society. 1998: 36.
44. van Dongen JJM, van den Beemd MWM, Schellekens M, Wolvers-Tettero ILM, Langerak AW, Groeneveld K. Analysis of malignant T-cells with the Vb antibody panel. The Immunologist 1996; 4: 37-40.
45. Van Dongen JJM and Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects. Clinica Chimica Acta. 1991; 198: 1-92.
46. Van Dongen JJM and Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clinica Chimica Acta. 1991; 198: 93-174.
47. Benhattar J, Delacretaz F, Martin P, Chaubert P, Costa J. Improved polymerase chain reaction detection of clonal T-cell lymphoid neoplasms. Diagnostic Molecular Pathology 1995; 4: 108-112.
48. Rezuke WN, Abernathy EC, Tsongalis GJ. Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications. Clinical Chemistry 1997; 43: 1814-1823.
49. Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y, Richter L, Grogan ™. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 76; 1990: 377-382.
50. Mittelman M, Karcher DS, Kammerman LA, Lessin LS. High Ia (HLA-DR) and low CD11b (Mol) expression may predict early conversion to leukemia in myelodysplastic syndromes. Am J Hematol 1993; 43: 165-171.
51. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C and van't Veer MB for the European Group for the Immunological classification of Leukemias (EGIL). The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias.
52. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995: 10: 1783-1786.
53. Bernier M, Massy M, Deleeuw N, Bron D, Debusscher L, Stryckmans P. Immunological definition of acute minimally differentiated myeloid leukemia (MO) and acute undifferentiated leukemia (AUL). Leukemia and Lymphoma 1995; 18 suppl 1: 13-17.
54. Adriaansen H, Van Dongen J, Kappers-Klunne M, Hahlen K, Van 't Veer M. Wijdenes de Bresser J, Holdrinet A, HarthoornLasthizen E, Abels J, Hooijkaas H. Terminal deoxynucleotidyl transferase positive subpopulations occur in the majority of ANLL: Implications for the detection of minimal disease. Leukemia 1990: 4: 404-411.
55. Hurwitz C. Raimondi S, Head D, Drance R, Miro J, Kalwinshy D, Ayers G, Behm F. Distinctive immunophenotypic features of t(8:21 )(q22q22) acute myeloblastic leukemia in children. Blood 1992: 80: 182-188.
56. Coustan-Smith E, Behm F, Hurwitz C, Rivera G, Campane D. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993; 7: 853-858.
57. Reading C, Estey E, Huh Y, Claxton D, Sanchez G, Terstappen L, O'Brien M, Baron S, Deisseroth A. Expression of unusual immunophenotype combinations in acute myelogeneous leukemia. Blood 1993; 81: 3083-3090.
58. Syrjala M, Anttila V, Ruutu T, Jansson S. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens. Leukemia 1994; 8: 1564-1570.
59. Pui C, Behm F. Crist W. Clinical and biological relevance of immunologic marker studies in childhood ALL. Blood 1993: 82: 383-362.
60. Van Dongen J, Breit T, Adriaansen H, Beishuizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992: 6: 47-52.
61. Reading C, Estey E, Huh Y, Claxton D, Sanchez G, Terstappen L, O'Brien M, Baron S, Deisseroth A. Expression of unusual immunophenotype combinations in acute myelogeneous leukemia. Blood 1993; 81: 3083-3090.
62. Adriaansen H, Jacobs B, Kappers-Klunne M, Hahlen K, Hooijkaas H, Van Dongen J. Detection of residual disease in AML patients by use of double immunologic marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 1993; 7:472-479.
63. Campana D. Applications of cytometry to study acute leukemia: In vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 1994; 18: 68-74.
64. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: Methodologie advances and clinical signififcance. Blood 1995; 85: 1416-1434.
65. Sievers E, Loken M. Detection of minimal residual disease in acyute myelogenous leukemia. J Fed Hem/Onc 1995; 17: 123-133.
66. Seivers E, Lange B, Buckley J, Smith F, Wells D, Daigneault-Creech C, Shults K, Bernstein I, Loken M. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 1996; 88: 1483-1488.
67. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Cytometry 1998; 34: 61-70.
68. The reimbursement is limited to T and B cells and CD4 and CD8 cells. Additional testing can be performed only for haematological malignancies, for congenital or live threatening acquired immune deficiencies and for sarcoidosis with a maximum of 12 additional antigens. This maximum can only be overruled for diagnostic procedures of acute malignant haemopathies.
69. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, Reiffers J, Boisseau MR, Bernard Ph. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878-1886.